12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Oasmia, Pharmasyntez sales and marketing update

Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in the Commonwealth of Independent States (CIS) to treat ovarian cancer, lung cancer and second-line...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >